AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Identify key components to include in your diversification checklist, ensuring broad exposure, appropriate risk, and alignment with retirement timing.
18,835 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
As copper markets gyrate in 2026, investors must choose between COPX miners and CPER futures for exposure. The decisi...
A young CEO transformed a Discord community into a talent funnel, driving the growth of a SpaceX-backed AI venture va...
Supermicro sits at the intersection of exploding AI demand and serious credibility concerns. This article breaks down...
NVIDIA and Micron delivered standout AI hardware results, but investors reacted differently as the AI demand mix shif...
As SpaceX IPO chatter grows, investors seek breadth over a single-name bet. A diversified space ETF offers exposure t...
Crypto markets have punished many altcoins this year, but opportunity can emerge from disciplined analysis. This guid...
OpenAI accelerates its shift from software to silicon and bio bets, unveiling a custom chip, a DRAM stake, and a majo...
Rising sticker prices keep reshaping the auto market, with the ford f-150 expensive price tag drawing renewed scrutin...
AMD and Marvell released quarterly results centered on AI infrastructure, highlighting different strategic bets in da...
Floating-rate Treasuries have provided steadier income as rate volatility persists. This piece examines how USFR deli...
Bitcoin is staging a comeback as technical indicators flash bullish. Traders eye a potential move toward $65,000 in t...